StockNews.AI
ADPT
StockNews.AI
131 days

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

1. ADPT will announce Q1 2025 financial results on May 1, 2025. 2. A conference call will follow the results announcement for detailed discussion. 3. ADPT specializes in immune-based diagnostics and treatments for diseases. 4. The company leverages its platform for partnerships and clinical diagnostics.

4m saved
Insight
Article

FAQ

Why Neutral?

The scheduled earnings release may lead to volatility but lacks groundbreaking news influence. Similar earnings announcements by peers resulted in mixed market reactions.

How important is it?

Earnings results could impact investor perception and stock price. However, this impact is considered moderate without significant new product announcements or news.

Why Short Term?

The immediate price impacts will surface post-earnings but may stabilize soon after. Previous earnings announcements showed short-lived fluctuations for ADPT.

Related Companies

MRNAEXASAMGN
April 10, 2025 16:05 ET  | Source: Adaptive Biotechnologies SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event. About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@adaptivebiotech.com ADAPTIVE MEDIAErica Jones, Associate Director, Corporate Communications845-344-7542media@adaptivebiotech.com

Related News